Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.55 |
| ▸ | PRSS12 | P56730 | 9/20 | 0.55 |
| ▸ | MAPT | P10636 | 5/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9660830 | 0.90 | RAB9A (0.58) | F10PRSS12MAPTTP53RXFP1 | |
| SCHEMBL647033 | 0.77 | MCL1 (0.65) | MAPTTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL16562057 | 0.76 | MAPT (0.72) | F10PRSS12MAPTTP53RXFP1 | |
| SCHEMBL16554278 | 0.74 | MAPT (0.69) | F10PRSS12MAPTTP53RXFP1 | |
| SCHEMBL12767900 | 0.74 | MAPT (0.69) | F10PRSS12MAPTTP53RXFP1 | |
| SCHEMBL12840765 | 0.74 | ALDH1A1 (0.55) | F10MAPTTP53RXFP1SMN1; SMN2 | |
| SCHEMBL5935569 | 0.74 | MAPT (0.79) | F10PRSS12MAPTTP53RXFP1 | |
| SCHEMBL10481440 | 0.73 | TASP1 (0.61) | F10MAPTTP53RXFP1NPC1 | |
| SCHEMBL4604503 | 0.72 | MAOB (0.77) | MAPTTP53RXFP1SMN1; SMN2NPC1 | |
| SCHEMBL3659600 | 0.71 | FFAR1 (0.89) | MAPTSMN1; SMN2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9102667-B2 | N-arylaminomethylene benzothiophenones for treatment of cardiovascular disease | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102667-B2 | N-arylaminomethylene benzothiophenones for treatment of cardiovascular disease | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2015-08-11 | — | — | US | disclosed |
| US-9102667-B2 | N-arylaminomethylene benzothiophenones for treatment of cardiovascular disease | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2015-08-11 | — | — | US | disclosed |
| US-20130289057-A1 | N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289057-A1 | N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2013-10-31 | — | — | US | disclosed |
| US-20130289057-A1 | N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE | FORSCHUNGSVERBUND BERLIN E.V. (DE) | 2013-10-31 | — | — | US | disclosed |
| WO-2012098172-A2 | N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE | Max-Delbrück-Centrum für Molekulare Medizin (DE) | 2012-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130289057-A1 | N-ARYLAMINOMETHYLENE BENZOTHIOPHENONES FOR TREATMENT OF CARDIOVASCULAR DISEASE | TNNT2, NAT1, PAH | F10 3502/4885PRSS12 1701/4885MAPT 4514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.